US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Tevogen Bio Holdings

1.01

+0.03163.23%

Post-market: 1.00-0.0100-0.99%16:33 EDT

Volume:750.67K

Turnover:756.41K

Market Cap:185.73M

PE:-14.42

High:1.03

Open:0.9895

Low:0.9700

Close:0.9784

Loading ...

Overview Company News Filings

Biotech Alert: Searches spiking for these stocks today

Tevogen Informs Public Shareholders About DRS Accounts And Differences to Brokerage Accounts

BRIEF-Tevogen CEO To Join Dialogue On Paths To Liquidity at BioNJ’s Fifteenth Annual Bio Partnering Conference

Tevogen CEO to Join Dialogue on Paths to Liquidity: Strategies for Adapting to a Volatile Market at Bionj’s Fifteenth Annual Bio Partnering Conference With Experts From J.p. Morgan, Rsm, and Cantor Fitzgerald

THOMSON REUTERS

Tevogen CEO to Join Dialogue on Paths to Liquidity: Strategies for Adapting to a Volatile Market at BioNJ’s Fifteenth Annual Bio Partnering Conference with Experts from J.P. Morgan, RSM, and Cantor Fitzgerald

Tevogen Bio Holdings Is Maintained at Buy by D. Boral Capital

BUZZ-Tevogen gains after it reaffirms revenue forecast for experimental oncology drugs

Tevogen sees launch year oncology business revenue $1B

Tevogen Reaffirms Oncology Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion

THOMSON REUTERS

Tevogen Reaffirms Oncology Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion

Tevogen Bio Announces 2025 Annual Meeting

Tevogen Bio Holdings Is Maintained at Buy by D. Boral Capital

Tevogen Bio Agrees With CD8 to Develop, Acquire Cell Therapy Production Facility

MT Newswires Live

Tevogen Bio Finalizes Agreement for Company’s Own Cell Therapy Production Facility

THOMSON REUTERS

Press Release: Tevogen Bio Finalizes Agreement for Company's Own Cell Therapy Production Facility

Tevogen Bio Commissions Databricks to Accelerate Development of PredicTcell, a Precision AI Tool for Target Prediction

Tevogen CEO to Join Dialogue on Paths to Liquidity: Strategies for Adapting to a Volatile Market at BioNJ’s Fifteenth Annual Bio Partnering Conference with Experts from J.P. Morgan, RSM, and Cantor Fitzgerald

Tevogen announces Tevogen Generics following Trump’s tariff-related statements

Tevogen Bio Holdings: Announces Newest Effort, Tevogen Generics

THOMSON REUTERS

Tevogen Bio Holdings: Initiative Seeks to Expedite Domestic Manufacturing of Unbranded Pharmaceuticals & Apis in US

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/TVGN/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"TVGN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TVGN\",,,,,undefined,":{"symbol":"TVGN","market":"US","secType":"STK","nameCN":"Tevogen Bio Holdings","latestPrice":1.01,"timestamp":1746216000000,"preClose":0.9784,"halted":0,"volume":750674,"hourTrading":{"tag":"盘后","latestPrice":1,"preClose":1.01,"latestTime":"16:33 EDT","volume":6736,"amount":6756.650555200001,"timestamp":1746218006650},"delay":0,"floatShares":22757419,"shares":183893433,"eps":-0.070045,"marketStatus":"Post-Mkt","change":0.0316,"latestTime":"05-02 16:33:33 EDT","open":0.9895,"high":1.03,"low":0.97,"amount":756405.9965292001,"amplitude":0.061325,"askPrice":1.02,"askSize":3103,"bidPrice":0.98,"bidSize":5446,"shortable":3,"etf":0,"ttmEps":-0.070045,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1746230400000},"marketStatusCode":4,"adr":0,"exchange":"NASDAQ","adjPreClose":0.9784,"preHourTrading":{"tag":"盘前","latestPrice":0.98,"preClose":0.9784,"latestTime":"09:23 EDT","volume":8404,"amount":8138.594956800001,"timestamp":1746192222253},"postHourTrading":{"tag":"盘后","latestPrice":1,"preClose":1.01,"latestTime":"16:33 EDT","volume":6736,"amount":6756.650555200001,"timestamp":1746218006650},"volumeRatio":0.155404},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TVGN\",,,,,undefined,":{"symbol":"TVGN","floatShares":22757419,"roa":"-746.67%","roe":"--","lyrEps":-0.070045,"volumeRatio":0.155404,"shares":183893433,"dividePrice":0,"high":1.03,"amplitude":0.061325,"preClose":0.9784,"low":0.97,"week52Low":0.2556,"pbRate":"-12.00","week52High":3.09,"institutionHeld":0,"latestPrice":1.01,"committee":0.274067,"eps":-0.070045,"divideRate":0,"volume":750674,"delay":0,"ttmEps":-0.070045,"open":0.9895,"prevYearClose":1.03,"prevWeekClose":0.9922,"prevMonthClose":1.03,"prevQuarterClose":1.08,"fiveDayClose":0.9922,"twentyDayClose":1,"sixtyDayClose":1.48},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"TVGN\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2532000582","title":"Biotech Alert: Searches spiking for these stocks today","url":"https://stock-news.laohu8.com/highlight/detail?id=2532000582","media":"TipRanks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532000582?lang=en_us&edition=fundamental","pubTime":"2025-05-02 00:15","pubTimestamp":1746116123,"startTime":"0","endTime":"0","summary":"These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:. Discover companies with rock-solid fundamentals in  TipRanks' Smart Value Newsletter.Receive undervalued stocks, resilient to market uncertainty,  delivered straight to your inbox.Tevogen Bio Holdings , 332% surge in interest. Pipeline and key clinical candidates for these companies:. Galmed is a clinical stage biopharmaceutical company focused on the development of Aramchol for liver and fibro-inflammatory diseases. The company has focused almost exclusively on developing Aramchol for the treatment of noncirrhotic nonalcoholic steatohepatitis, or NASH, and are currently developing Aramchol for Primary Sclerosing Cholangitis, or PSC, and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of liver disease.CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commer","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/biotech-alert-searches-spiking-stocks-161523387.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/biotech-alert-searches-spiking-stocks-161523387.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BCDAW","NVS","RGLS","IE0002141913.USD","BK4007","TVGN","BK4532","LU0070302665.USD","IE00BFTCPJ56.SGD","BK4585","IE00B4R5TH58.HKD","BK4588","BK4139","SWTX","LU0208291251.USD","IE00BJT1NW94.SGD","MKKGY","LU0211331839.USD","CGON","BK4578","BCDA","IE00B2B36J28.USD","IE0009355771.USD","IE00BJJMRZ35.SGD","LU0320765489.SGD","SNTI","TVGNW","BK4539","CMMB","GLMD"],"gpt_icon":0},{"id":"2531726767","title":"Tevogen Informs Public Shareholders About DRS Accounts And Differences to Brokerage Accounts","url":"https://stock-news.laohu8.com/highlight/detail?id=2531726767","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531726767?lang=en_us&edition=fundamental","pubTime":"2025-04-30 01:48","pubTimestamp":1745948880,"startTime":"0","endTime":"0","summary":"WARREN, N.J., April 29, 2025  -- Tevogen  , today informed shareholders about several differences between holding shares in Direct Registration System  accounts and holding them in brokerage accounts.A DRS account is an alternative to using a brokerage account and Tevogen encourages shareholders to explore the differences. DRS accounts ensure your shares are registered directly in your name and not held through intermediary brokers, allowing shareholder to exercise direct control over their shares. DRS accounts may also have reduced transaction and account maintenance costs for shareholders. Brokerage accounts may provide greater access to tools, and selling shares in this type of account may be quicker when compared to a DRS account. Investors may also incur certain costs in connection with transferring shares in and out of a brokerage account.For more information about these and other differences, please contact the Company’s transfer agent, Continental Stock Transfer & Trust.Tevogen","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tevogen-informs-public-shareholders-drs-174800183.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B19Z4B17.USD","TVGN","IE00B7SZL793.SGD","BK4187","IE00B66KJ199.SGD","DRS","TVGNW","IE0031619046.USD"],"gpt_icon":0},{"id":"2531739891","title":"BRIEF-Tevogen CEO To Join Dialogue On Paths To Liquidity at BioNJ’s Fifteenth Annual Bio Partnering Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2531739891","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531739891?lang=en_us&edition=fundamental","pubTime":"2025-04-29 20:49","pubTimestamp":1745930987,"startTime":"0","endTime":"0","summary":"BRIEF-Tevogen CEO To Join Dialogue On Paths To Liquidity at BioNJ’s Fifteenth Annual Bio Partnering Conference April 29 (Reuters) - JPMorgan Chase & Co JPM.N:TEVOGEN CEO TO JOIN DIALOGUE ON PATHS TO L","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250429:nTUA2BSXTT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0234572021.USD","BK4581","LU0964807845.USD","LU1244550577.SGD","LU0496365809.HKD","SG9999002224.SGD","LU0320765646.SGD","SG9999002232.USD","LU0323591593.USD","LU1548497426.USD","LU1267930490.SGD","LU2023250843.SGD","LU1894683348.USD","BK4550","IE00B775SV38.USD","LU0345769128.USD","LU0787776722.HKD","LU1914381329.SGD","LU2430703178.SGD","IE00BJTD4V19.USD","BK4585","LU0683600562.USD","IE00BWXC8680.SGD","IE00BDCRKT87.USD","LU0208291251.USD","IE00BKVL7J92.USD","LU0070302665.USD","LU0211326755.USD","IE000M9KFDE8.USD","BK4516","LU0976567544.SGD","TVGN","LU2430703251.USD","LU1629891620.HKD","IE0034235303.USD","LU2237443465.HKD","LU1988902786.USD","IE00BYXW3230.USD","LU0868494617.USD","TVGNW","LU2430703095.HKD","IE00BJLML261.HKD","LU2054465674.USD","LU0256863811.USD","LU0345769631.USD","LU2237443895.HKD","IE0034235295.USD","LU0211326839.USD","BK4588","LU0820562030.AUD"],"gpt_icon":1},{"id":"2531787292","title":"Tevogen CEO to Join Dialogue on Paths to Liquidity: Strategies for Adapting to a Volatile Market at Bionj’s Fifteenth Annual Bio Partnering Conference With Experts From J.p. Morgan, Rsm, and Cantor Fitzgerald","url":"https://stock-news.laohu8.com/highlight/detail?id=2531787292","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531787292?lang=en_us&edition=fundamental","pubTime":"2025-04-29 20:00","pubTimestamp":1745928000,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250429:nTUA2BSXTT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1548497426.USD","LU0345769631.USD","LU1032466523.USD","IE00BFXG1179.USD","LU0267386448.USD","LU2552382132.HKD","LU1894683348.USD","IE00BJTD4V19.USD","LU1261432733.SGD","IE00BN8TJ469.HKD","LU0345769128.USD","IE00B1BXHZ80.USD","IE00BJLML261.HKD","LU1145028129.USD","LU1363072403.SGD","LU1720051017.SGD","BK4207","LU0320765646.SGD","LU1119994496.HKD","TVGN","LU0943347566.SGD","BK4533","LU0238689110.USD","IE00BKVL7J92.USD","LU0211326839.USD","LU2242649171.HKD","LU0208291251.USD","LU2430703251.USD","LU2505996509.AUD","LU1917777945.USD","LU0683600562.USD","LU0203345920.USD","LU2023250843.SGD","LU2237443382.USD","LU1551013425.SGD","LU1670628061.USD","LU2592432038.USD","BK4534","IE00BZ1G4Q59.USD","LU0787776722.HKD","TVGNW","IE00BBT3K403.USD","LU2237443978.SGD","BK4585","LU0496365809.HKD","LU2106854487.HKD","LU0976567544.SGD","LU0310799852.SGD","IE00BKDWB100.SGD","SG9999002232.USD"],"gpt_icon":0},{"id":"2531339647","title":"Tevogen CEO to Join Dialogue on Paths to Liquidity: Strategies for Adapting to a Volatile Market at BioNJ’s Fifteenth Annual Bio Partnering Conference with Experts from J.P. Morgan, RSM, and Cantor Fitzgerald","url":"https://stock-news.laohu8.com/highlight/detail?id=2531339647","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531339647?lang=en_us&edition=fundamental","pubTime":"2025-04-29 20:00","pubTimestamp":1745928000,"startTime":"0","endTime":"0","summary":"WARREN, N.J., April 29, 2025  -- Tevogen  , today reminds that CEO Dr. Ryan Saadi MD, MPH will participate in BioNJ’s Fifteenth Annual Bio Partnering Conference. Dr. Saadi will be featured on the panel discussion titled Paths to Liquidity: Strategies for Adapting to a Volatile Market, moderated by David C Schwartz, Partner at Morgan Lewis. Along with Dr. Ryan Saadi, the panel will also include commentary from Matt Vamvakis, MBA, Managing Director, J.P. Morgan Private Bank, Amanda Laskey, Life Sciences Senior Analyst, RSM US, and Kee Colon, MBA, Managing Director, Cantor Fitzgerald.“The conference’s action-packed agenda, featuring 1:1 partnering sessions, company pitch presentations, the Industry Connections Desk, exhibits, extensive networking opportunities and engaging plenary discussions, was thoughtfully designed to provide entrepreneurs with a dynamic environment geared toward growth and collaboration,” said BioNJ President and CEO Debbie Hart. “With that in mind, we’re thrilled to","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tevogen-ceo-join-dialogue-paths-120000040.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["TVGNW","BK4139","TVGN"],"gpt_icon":0},{"id":"2531782825","title":"Tevogen Bio Holdings Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2531782825","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531782825?lang=en_us&edition=fundamental","pubTime":"2025-04-29 19:38","pubTimestamp":1745926680,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/TVGN/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 29, 2025 07:38 ET (11:38 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TVGN"],"gpt_icon":0},{"id":"2531826960","title":"BUZZ-Tevogen gains after it reaffirms revenue forecast for experimental oncology drugs","url":"https://stock-news.laohu8.com/highlight/detail?id=2531826960","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531826960?lang=en_us&edition=fundamental","pubTime":"2025-04-29 04:57","pubTimestamp":1745873831,"startTime":"0","endTime":"0","summary":"BUZZ-Tevogen gains after it reaffirms revenue forecast for experimental oncology drugs** Shares of drug developer Tevogen TVGN.O up 49.35% at $1.40 in after-market trading** Company reaffirms top-line revenue forecast for its experimental oncology drugs** Projects $1 billion in revenue in its launch year and a cumulative 5-year estimate of between $10 billion and $14 billion** Stock down 9% YTD  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250428:nL4N3R61S9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TVGN"],"gpt_icon":0},{"id":"2531269463","title":"Tevogen sees launch year oncology business revenue $1B","url":"https://stock-news.laohu8.com/highlight/detail?id=2531269463","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531269463?lang=en_us&edition=fundamental","pubTime":"2025-04-29 04:50","pubTimestamp":1745873433,"startTime":"0","endTime":"0","summary":"Tevogen (TVGN) reaffirms its top-line revenue forecast for its oncology pipeline, projecting $1B in revenue in its launch year and a cumulative fiv...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tevogen-sees-launch-year-oncology-business-revenue-1b?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tevogen-sees-launch-year-oncology-business-revenue-1b?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TVGN","BK4139"],"gpt_icon":0},{"id":"2531652752","title":"Tevogen Reaffirms Oncology Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=2531652752","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531652752?lang=en_us&edition=fundamental","pubTime":"2025-04-29 04:36","pubTimestamp":1745872617,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250428:nTUA7Q52VY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TVGNW","TVGN","BK4139"],"gpt_icon":0},{"id":"2531261385","title":"Tevogen Reaffirms Oncology Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=2531261385","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531261385?lang=en_us&edition=fundamental","pubTime":"2025-04-29 04:36","pubTimestamp":1745872560,"startTime":"0","endTime":"0","summary":"Reflects business philosophy of commercial success through patient accessibility. Recently executed agreement with CD 8 Technology Services LLC providing up to $50 million for Company’s dedicated R&D and manufacturing facility; no impact on shareholder equity. WARREN, N.J., April 28, 2025  -- Tevogen  , reaffirms its top-line revenue forecast for its oncology pipeline, projecting $1 billion in revenue in its launch year and a cumulative 5-year estimate of between $10 billion and $14 billion. The forecast reflects the company’s unique, faster, and cost-efficient drug development model which has the potential to serve as a blueprint to ensure sustainable medical innovation for years to come.Factors that could cause actual results, performance, or achievements to differ from those expressed or implied by forward-looking statements include, but are not limited to: that Tevogen will need to raise additional capital to execute its business plan, which may not be available on acceptable terms","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tevogen-reaffirms-oncology-top-line-203600841.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"Tevogen Reaffirms Oncology Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["TVGNW","TVGN"],"gpt_icon":0},{"id":"2530169399","title":"Tevogen Bio Announces 2025 Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2530169399","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530169399?lang=en_us&edition=fundamental","pubTime":"2025-04-26 02:33","pubTimestamp":1745605980,"startTime":"0","endTime":"0","summary":"WARREN, N.J., April 25, 2025  -- Tevogen Bio Holdings Inc.   today announced that the Company will hold its 2025 annual meeting of stockholders  via live webcast at 11 a.m. Eastern Time on June 23, 2025. Stockholders of record as of April 30, 2025, will be asked to vote on the re-election of two incumbent director nominees, and the ratification of the Company’s independent registered public accounting firm.Tevogen Bio encourages all stockholders of record as of April 30, 2025, to participate in this year’s vote. Proxy materials, including detailed instructions for voting, will be distributed or made available in accordance with Securities and Exchange Commission  regulations to stockholders of record as of April 30, 2025. If you are a stockholder and provide your 16-digit control number, which can be found on your Notice of Internet Availability, proxy card, or voting instruction form, you will be able to vote your shares at the Annual Meeting.The Company intends to disclose the Annual","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tevogen-bio-announces-2025-annual-183300444.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["TVGNW","BK4139","TVGN"],"gpt_icon":0},{"id":"2529038388","title":"Tevogen Bio Holdings Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2529038388","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529038388?lang=en_us&edition=fundamental","pubTime":"2025-04-21 20:06","pubTimestamp":1745237160,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/TVGN/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 21, 2025 08:06 ET (12:06 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TVGN"],"gpt_icon":0},{"id":"2528778487","title":"Tevogen Bio Agrees With CD8 to Develop, Acquire Cell Therapy Production Facility","url":"https://stock-news.laohu8.com/highlight/detail?id=2528778487","media":"MT Newswires Live","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528778487?lang=en_us&edition=fundamental","pubTime":"2025-04-18 03:50","pubTimestamp":1744919432,"startTime":"0","endTime":"0","summary":"Tevogen Bio  said Thursday it has agreed with CD 8 Technology Services to develop or acquire a facility for pre-clinical research and cell therapy production. Financial details were not disclosed.The new facility will support both research and GMP cell therapy manufacturing, with Tevogen Bio providing the main staff and operations, the company said.CD8 is associated with Manmohan Patel, who beneficially owns more than 5% of the company's common stock.Tevogen Bio expects the agreement to help it avoid high upfront costs usually needed to build GMP facilities at scale, it added.The agreement will last for 12 months at first and will automatically renew, matching the company's earlier financial forecasts, according to the company.Shares of the company were down about 4.9% in recent trading.Price: 0.97, Change: -0.05, Percent Change: -4.80","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","TVGN"],"gpt_icon":0},{"id":"2528727132","title":"Tevogen Bio Finalizes Agreement for Company’s Own Cell Therapy Production Facility","url":"https://stock-news.laohu8.com/highlight/detail?id=2528727132","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528727132?lang=en_us&edition=fundamental","pubTime":"2025-04-18 02:55","pubTimestamp":1744916108,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250417:nFWN3QV39D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TVGN","BK4139"],"gpt_icon":0},{"id":"2528153727","title":"Press Release: Tevogen Bio Finalizes Agreement for Company's Own Cell Therapy Production Facility","url":"https://stock-news.laohu8.com/highlight/detail?id=2528153727","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528153727?lang=en_us&edition=fundamental","pubTime":"2025-04-18 02:54","pubTimestamp":1744916040,"startTime":"0","endTime":"0","summary":"-- The agreement would facilitate providing Tevogen Bio with in-house cell. -- Formalized agreement aligns with previously announced topline forecasts. This press release contains certain forward-looking statements, including without limitation statements relating to: Tevogen's plans for its research and manufacturing capabilities; Tevogen's ability to build GMP capabilities at scale; the prospective benefits of the agreement with CD8; expectations regarding future product revenues; expectations regarding the healthcare and biopharmaceutical industries; and Tevogen's development of, the potential benefits of, and patient access to its product candidates for the treatment of infectious diseases and cancer. Forward-looking statements can sometimes be identified by words such as \"may,\" \"could,\" \"would,\" \"expect,\" \"anticipate,\" \"possible,\" \"potential, \" \"goal,\" \"opportunity,\" \"project,\" \"believe,\" \"future,\" and similar words and expressions or their opposites. These statements are based on","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TVGN"],"gpt_icon":0},{"id":"2527298664","title":"Tevogen Bio Commissions Databricks to Accelerate Development of PredicTcell, a Precision AI Tool for Target Prediction","url":"https://stock-news.laohu8.com/highlight/detail?id=2527298664","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527298664?lang=en_us&edition=fundamental","pubTime":"2025-04-16 02:03","pubTimestamp":1744740180,"startTime":"0","endTime":"0","summary":"WARREN, N.J., April 15, 2025  -- Tevogen  , today announced the commission of Databricks, Inc., a leader in data, analytics and artificial intelligence , with an aim to accelerate the development of PredicTcell, the Company’s proprietary AI-driven target prediction model for precision immunotherapy.Databricks will provide a dedicated data engineering team and its expertise in building, scaling, and governing data and AI systems. This support should advance PredicTcell's capabilities in modeling immunologically active HLA+ peptide complexes and predicting T cell receptor  engagement with those complexes. The efforts will be directed to bring two foundational models to bear based on the company’s revolutionary ExacTcellplatform: predicting immunologically active peptides through machine learning and developing a predictive T cell receptor binding model.This announcement marks the third foundational support pillar for Tevogen.AI, the Company’s AI initiative which aims to transform precisi","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tevogen-bio-commissions-databricks-accelerate-180300735.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["TVGNW","TVGN","AAQC"],"gpt_icon":0},{"id":"2527111133","title":"Tevogen CEO to Join Dialogue on Paths to Liquidity: Strategies for Adapting to a Volatile Market at BioNJ’s Fifteenth Annual Bio Partnering Conference with Experts from J.P. Morgan, RSM, and Cantor Fitzgerald","url":"https://stock-news.laohu8.com/highlight/detail?id=2527111133","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527111133?lang=en_us&edition=fundamental","pubTime":"2025-04-15 01:53","pubTimestamp":1744653180,"startTime":"0","endTime":"0","summary":"WARREN, N.J., April 14, 2025  -- Tevogen  , today announces CEO Dr. Ryan Saadi, MD, MPH, will participate in BioNJ’s Fifteenth Annual Bio Partnering Conference. Dr. Saadi will be featured on the panel discussion titled Paths to Liquidity: Strategies for Adapting to a Volatile Market, moderated by David C Schwartz, Partner at Morgan Lewis. Along with Dr. Ryan Saadi, the panel will also include commentary from Matt Vamvakis, MBA, Managing Director, J.P. Morgan Private Bank, Amanda Laskey, Life Sciences Senior Analyst, RSM US, and Kee Colon, MBA, Managing Director, Cantor Fitzgerald.“The conference’s action-packed agenda, featuring 1:1 partnering sessions, company pitch presentations, the Industry Connections Desk, exhibits, extensive networking opportunities and engaging plenary discussions, was thoughtfully designed to provide entrepreneurs with a dynamic environment geared toward growth and collaboration,” said BioNJ President and CEO Debbie Hart. “With that in mind, we’re thrilled to ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tevogen-ceo-join-dialogue-paths-175300708.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["TVGN","TVGNW"],"gpt_icon":0},{"id":"2526910312","title":"Tevogen announces Tevogen Generics following Trump’s tariff-related statements","url":"https://stock-news.laohu8.com/highlight/detail?id=2526910312","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526910312?lang=en_us&edition=fundamental","pubTime":"2025-04-10 02:55","pubTimestamp":1744224909,"startTime":"0","endTime":"0","summary":"Tevogen (TVGN) announced its newest effort: Tevogen Generics. “This effort is in response to the growing national focus on pharmaceutical affordabi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tevogen-announces-tevogen-generics-following-trumps-tariff-related-statements?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tevogen-announces-tevogen-generics-following-trumps-tariff-related-statements?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TVGN","BK4139"],"gpt_icon":0},{"id":"2526128363","title":"Tevogen Bio Holdings: Announces Newest Effort, Tevogen Generics","url":"https://stock-news.laohu8.com/highlight/detail?id=2526128363","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526128363?lang=en_us&edition=fundamental","pubTime":"2025-04-10 02:46","pubTimestamp":1744224393,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250409:nFWN3QN1AF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","TVGN"],"gpt_icon":0},{"id":"2526031289","title":"Tevogen Bio Holdings: Initiative Seeks to Expedite Domestic Manufacturing of Unbranded Pharmaceuticals & Apis in US","url":"https://stock-news.laohu8.com/highlight/detail?id=2526031289","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526031289?lang=en_us&edition=fundamental","pubTime":"2025-04-10 02:46","pubTimestamp":1744224393,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250409:nFWN3QN1AF:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TVGN","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":78,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TVGN\",params:#limit:5,,,undefined,":[{"market":"US","date":"2024-02-15","symbol":"TVGN","reason":null,"defaultRemindTime":1708007400000,"announcedDate":"2024-02-14","type":"delisting","dateTimestamp":1707973200000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TVGN\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"TVGN\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":1,"updateTime":1741752000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/TVGN\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"TVGN","date":"2025-05-01","current":-13.797989,"percent":0.625899,"low":-87.683882,"twenty":-32.748667,"median":-22.02776,"eighty":-7.830197,"high":-2.106753,"avg":-22.902346,"sd":16.152967,"marketCap":189410235},"quantilePoints":[{"date":"2024-03-01","current":-58.029616,"twenty":-57.969868,"median":-57.58151,"eighty":-55.109463,"marketCap":1279054027},{"date":"2024-03-08","current":-55.116932,"twenty":-57.969868,"median":-57.3948,"eighty":-55.049716,"marketCap":1214854404},{"date":"2024-03-15","current":-48.544723,"twenty":-57.715942,"median":-55.116932,"eighty":-49.664986,"marketCap":1069993717},{"date":"2024-03-22","current":-31.890149,"twenty":-57.596447,"median":-52.465643,"eighty":-44.108482,"marketCap":702903564},{"date":"2024-03-28","current":-25.919148,"twenty":-57.357457,"median":-49.38492,"eighty":-32.983824,"marketCap":571294337},{"date":"2024-04-05","current":-25.392625,"twenty":-55.998205,"median":-48.543977,"eighty":-28.607629,"marketCap":559689021},{"date":"2024-04-12","current":-18.446995,"twenty":-55.146806,"median":-35.064227,"eighty":-23.267262,"marketCap":406597612},{"date":"2024-04-19","current":-15.833048,"twenty":-54.915285,"median":-32.71989,"eighty":-19.118705,"marketCap":348982566},{"date":"2024-04-26","current":-6.348156,"twenty":-53.503754,"median":-29.329228,"eighty":-17.595595,"marketCap":139922255},{"date":"2024-05-03","current":-7.365355,"twenty":-52.428301,"median":-25.919148,"eighty":-15.026459,"marketCap":162342739},{"date":"2024-05-10","current":-2.698495,"twenty":-50.822591,"median":-23.061357,"eighty":-9.708944,"marketCap":163198734},{"date":"2024-05-17","current":-2.422494,"twenty":-49.291565,"median":-20.164731,"eighty":-7.316959,"marketCap":146506832},{"date":"2024-05-24","current":-2.231961,"twenty":-48.694091,"median":-18.372311,"eighty":-2.71254,"marketCap":134983822},{"date":"2024-05-31","current":-2.106753,"twenty":-48.544425,"median":-17.961548,"eighty":-2.656034,"marketCap":127411559},{"date":"2024-06-07","current":-8.033143,"twenty":-47.558444,"median":-17.550785,"eighty":-2.656034,"marketCap":148265257},{"date":"2024-06-14","current":-7.903098,"twenty":-44.108482,"median":-15.833048,"eighty":-2.68298,"marketCap":145865070},{"date":"2024-06-21","current":-6.795171,"twenty":-36.221832,"median":-12.47226,"eighty":-2.696046,"marketCap":125416385},{"date":"2024-06-28","current":-6.570165,"twenty":-35.295748,"median":-12.322891,"eighty":-2.697026,"marketCap":121263525},{"date":"2024-07-05","current":-6.173255,"twenty":-33.757254,"median":-8.033143,"eighty":-2.703177,"marketCap":113937879},{"date":"2024-07-12","current":-6.299258,"twenty":-33.071802,"median":-7.830197,"eighty":-2.721904,"marketCap":116263481},{"date":"2024-07-15","current":-6.435162,"twenty":-32.983824,"median":-7.830197,"eighty":-2.721904,"marketCap":118771808},{"date":"2024-08-02","current":-5.57114,"twenty":-32.895846,"median":-7.830197,"eighty":-2.721904,"marketCap":102824824},{"date":"2024-08-09","current":-5.526139,"twenty":-32.222045,"median":-7.468419,"eighty":-3.563104,"marketCap":101994252},{"date":"2024-08-16","current":-20.612899,"twenty":-30.545833,"median":-7.468046,"eighty":-4.127144,"marketCap":122353801},{"date":"2024-08-23","current":-17.275162,"twenty":-29.265149,"median":-7.830197,"eighty":-4.681198,"marketCap":102541700},{"date":"2024-08-30","current":-14.308285,"twenty":-28.407028,"median":-7.866648,"eighty":-5.281333,"marketCap":84930944},{"date":"2024-09-06","current":-12.936966,"twenty":-27.171154,"median":-9.617885,"eighty":-5.454137,"marketCap":76791088},{"date":"2024-09-13","current":-14.230663,"twenty":-25.708539,"median":-12.097501,"eighty":-5.499138,"marketCap":84470197},{"date":"2024-09-20","current":-12.649478,"twenty":-24.871927,"median":-12.454498,"eighty":-5.544139,"marketCap":75084620},{"date":"2024-09-27","current":-11.784139,"twenty":-23.267262,"median":-12.36199,"eighty":-5.658262,"marketCap":69948149},{"date":"2024-10-04","current":-8.756889,"twenty":-21.942215,"median":-12.240382,"eighty":-5.887588,"marketCap":51979034},{"date":"2024-10-11","current":-9.208245,"twenty":-21.329829,"median":-12.040003,"eighty":-6.069393,"marketCap":54658190},{"date":"2024-10-18","current":-39.673363,"twenty":-24.871927,"median":-12.127687,"eighty":-6.141394,"marketCap":235492672},{"date":"2024-10-25","current":-73.596963,"twenty":-29.393307,"median":-12.327491,"eighty":-6.173255,"marketCap":436855971},{"date":"2024-10-31","current":-70.722082,"twenty":-31.779361,"median":-12.436737,"eighty":-6.180635,"marketCap":419791285},{"date":"2024-11-08","current":-32.773648,"twenty":-33.757254,"median":-12.633666,"eighty":-6.224556,"marketCap":194537424},{"date":"2024-11-15","current":-42.548244,"twenty":-38.983392,"median":-12.936966,"eighty":-6.285578,"marketCap":252557358},{"date":"2024-11-22","current":-36.270609,"twenty":-39.155884,"median":-13.187081,"eighty":-6.299438,"marketCap":287084045},{"date":"2024-11-29","current":-28.972255,"twenty":-38.235922,"median":-13.602501,"eighty":-6.300158,"marketCap":229317133},{"date":"2024-12-06","current":-23.222036,"twenty":-37.373458,"median":-13.816575,"eighty":-6.348156,"marketCap":183803809},{"date":"2024-12-13","current":-22.337387,"twenty":-36.270609,"median":-14.269474,"eighty":-6.435162,"marketCap":176801759},{"date":"2024-12-20","current":-21.33331,"twenty":-36.221832,"median":-15.004006,"eighty":-6.508963,"marketCap":168854432},{"date":"2024-12-27","current":-23.222036,"twenty":-35.303209,"median":-15.833048,"eighty":-6.557925,"marketCap":183803809},{"date":"2025-01-03","current":-23.443198,"twenty":-34.373394,"median":-17.065337,"eighty":-6.580965,"marketCap":185554321},{"date":"2025-01-10","current":-28.52993,"twenty":-33.790638,"median":-17.550785,"eighty":-6.670967,"marketCap":225816108},{"date":"2025-01-17","current":-26.760632,"twenty":-33.439732,"median":-17.684618,"eighty":-6.873653,"marketCap":211812008},{"date":"2025-01-24","current":-30.52039,"twenty":-33.171426,"median":-18.032197,"eighty":-7.005548,"marketCap":241570720},{"date":"2025-01-31","current":-29.635741,"twenty":-33.528197,"median":-18.446995,"eighty":-7.075423,"marketCap":234568670},{"date":"2025-02-07","current":-31.405039,"twenty":-33.171426,"median":-19.295444,"eighty":-7.138439,"marketCap":248572770},{"date":"2025-02-14","current":-34.501311,"twenty":-33.892862,"median":-20.164731,"eighty":-7.192457,"marketCap":273079945},{"date":"2025-02-21","current":-34.280148,"twenty":-34.280148,"median":-20.612899,"eighty":-7.244366,"marketCap":271329432},{"date":"2025-02-28","current":-27.645281,"twenty":-34.280148,"median":-21.570546,"eighty":-7.365355,"marketCap":218814058},{"date":"2025-03-07","current":-24.327847,"twenty":-34.058986,"median":-22.031836,"eighty":-7.370735,"marketCap":192556371},{"date":"2025-03-14","current":-24.54901,"twenty":-33.906622,"median":-22.226806,"eighty":-7.443187,"marketCap":194306884},{"date":"2025-03-21","current":-25.875983,"twenty":-33.837824,"median":-22.558549,"eighty":-7.452187,"marketCap":204809958},{"date":"2025-03-28","current":-26.53947,"twenty":-33.616662,"median":-23.000874,"eighty":-7.454567,"marketCap":210061496},{"date":"2025-04-04","current":-13.396106,"twenty":-33.174337,"median":-23.222036,"eighty":-7.467672,"marketCap":183893433},{"date":"2025-04-11","current":-13.396106,"twenty":-33.15978,"median":-22.669131,"eighty":-7.468419,"marketCap":183893433},{"date":"2025-04-17","current":-13.664028,"twenty":-32.994496,"median":-22.447968,"eighty":-7.468419,"marketCap":187571301},{"date":"2025-04-25","current":-13.530067,"twenty":-32.809553,"median":-22.063146,"eighty":-7.757841,"marketCap":185732367},{"date":"2025-05-01","current":-13.797989,"twenty":-32.748667,"median":-22.02776,"eighty":-7.830197,"marketCap":189410235}],"updateTime":1746203291967}}}